The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Proteasome inhibitors

Proteasome inhibitors

Proteasome inhibitors bind to the proteasome and prevent degradation of proteins involved in various signaling cascades. Preclinical studies in AML indicate proteasome inhibition disrupts proliferative cell signaling pathways, has cytotoxic synergism with other chemotherapies, and induces autophagy. For example, in AML, bortezomib is being investigated with combination chemotherapy regimens.

| |

All Interventions